Compile Data Set for Download or QSAR
Report error Found 59 Enz. Inhib. hit(s) with all data for entry = 9156
TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081196(US9475814, 13 | CHEMBL3422015 | US10065961, Compou...)
Affinity DataKi:  3nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251923(US9475814, 25 | BDBM272562 | US10683295, Compound ...)
Affinity DataKi:  3nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251909(US9475814, 7 | US10065961, Compound 7 | US10683295...)
Affinity DataKi:  4nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251907(US9475814, 5 | US10065961, Compound 5 | US10683295...)
Affinity DataKi:  5nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081399(US9475814, 19 | CHEMBL3422016 | US10065961, Compou...)
Affinity DataKi:  6nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251918(US9475814, 17 | US10065961, Compound 17 | US106832...)
Affinity DataKi:  7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251918(US9475814, 17 | US10065961, Compound 17 | US106832...)
Affinity DataKi:  7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251910(US9475814, 8 | US10065961, Compound 8 | US10683295...)
Affinity DataKi:  7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081293(US9475814, 30 | CHEMBL3422007 | US10065961, Compou...)
Affinity DataKi:  10nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081293(US9475814, 30 | CHEMBL3422007 | US10065961, Compou...)
Affinity DataKi:  10nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251916(US9475814, 15 | US10065961, Compound 15 | US106832...)
Affinity DataKi:  11nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251908(US9475814, 6 | US10065961, Compound 6 | US10683295...)
Affinity DataKi:  11nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251920(US9475814, 20 | US10065961, Compound 20 | US106832...)
Affinity DataKi:  12nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081195(US9475814, 1 | CHEMBL3422010 | US10065961, Compoun...)
Affinity DataKi:  16nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081195(US9475814, 1 | CHEMBL3422010 | US10065961, Compoun...)
Affinity DataKi:  16nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251911(US9475814, 9 | US10065961, Compound 9 | US10683295...)
Affinity DataKi:  19nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251919(US9475814, 18 | US10065961, Compound 18 | US106832...)
Affinity DataKi:  20nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251922(US9475814, 22 | US10065961, Compound 22 | US106832...)
Affinity DataKi:  21nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251928(US9475814, 31 | US10065961, Compound 31 | US106832...)
Affinity DataKi:  22nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251928(US9475814, 31 | US10065961, Compound 31 | US106832...)
Affinity DataKi:  22nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251927(US9475814, 29 | US10065961, Compound 29 | US106832...)
Affinity DataKi:  23nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251905(US9475814, 2 | US10065961, Compound 2 | US10683295...)
Affinity DataKi:  26nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081197(US9475814, 23 | CHEMBL3422017 | US10065961, Compou...)
Affinity DataKi:  29nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081197(US9475814, 23 | CHEMBL3422017 | US10065961, Compou...)
Affinity DataKi:  29nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM445679((R)-(3-(2,5-dimethylthiazol- 4-yl)-8-methyl-5,6-di...)
Affinity DataKi:  32nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251912(US9475814, 10 | US10065961, Compound 10 | US106832...)
Affinity DataKi:  36nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251921(US9475814, 21 | US10065961, Compound 21 | US106832...)
Affinity DataKi:  38nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251915(US9475814, 14 | US10065961, Compound 14 | US106832...)
Affinity DataKi:  42nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US9475814, 11 | US10065961, Compound 11 | US106832...)
Affinity DataKi:  44nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US9475814, 11 | US10065961, Compound 11 | US106832...)
Affinity DataKi:  44nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM445706(US10683295, Compound 27)
Affinity DataKi:  51nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251906(US9475814, 4 | US10065961, Compound 4 | US10683295...)
Affinity DataKi:  56nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251926(US9475814, 28 | US10065961, Compound 28 | US106832...)
Affinity DataKi:  68nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251914(US9475814, 12 | US10065961, Compound 12 | US106832...)
Affinity DataKi:  70nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081363(US9475814, 3 | CHEMBL3422012 | US10065961, Compoun...)
Affinity DataKi:  83nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081363(US9475814, 3 | CHEMBL3422012 | US10065961, Compoun...)
Affinity DataKi:  83nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081293(US9475814, 30 | CHEMBL3422007 | US10065961, Compou...)
Affinity DataKi:  5.93E+3nMAssay Description:NK2: Binding assays were performed in a 25 mM HEPES/1 mM CaCl2/5 mM MgCl2/0.5% BSA/10 μg/ml saponin, at pH 7.4. Binding assays consisted of 25 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251918(US9475814, 17 | US10065961, Compound 17 | US106832...)
Affinity DataKi:  6.06E+3nMAssay Description:NK1: The following radioligand: [3H] substance P (PerkinElmer Cat#NET111520) was used in this assay. Binding assays were performed in a 50 mM Tris/5 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251918(US9475814, 17 | US10065961, Compound 17 | US106832...)
Affinity DataKi:  9.95E+3nMAssay Description:NK2: Binding assays were performed in a 25 mM HEPES/1 mM CaCl2/5 mM MgCl2/0.5% BSA/10 μg/ml saponin, at pH 7.4. Binding assays consisted of 25 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081363(US9475814, 3 | CHEMBL3422012 | US10065961, Compoun...)
Affinity DataKi: >1.00E+4nMAssay Description:NK1: The following radioligand: [3H] substance P (PerkinElmer Cat#NET111520) was used in this assay. Binding assays were performed in a 50 mM Tris/5 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251928(US9475814, 31 | US10065961, Compound 31 | US106832...)
Affinity DataKi: >1.00E+4nMAssay Description:NK2: Binding assays were performed in a 25 mM HEPES/1 mM CaCl2/5 mM MgCl2/0.5% BSA/10 μg/ml saponin, at pH 7.4. Binding assays consisted of 25 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251928(US9475814, 31 | US10065961, Compound 31 | US106832...)
Affinity DataKi: >1.00E+4nMAssay Description:NK1: The following radioligand: [3H] substance P (PerkinElmer Cat#NET111520) was used in this assay. Binding assays were performed in a 50 mM Tris/5 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081363(US9475814, 3 | CHEMBL3422012 | US10065961, Compoun...)
Affinity DataKi: >1.00E+4nMAssay Description:NK2: Binding assays were performed in a 25 mM HEPES/1 mM CaCl2/5 mM MgCl2/0.5% BSA/10 μg/ml saponin, at pH 7.4. Binding assays consisted of 25 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081197(US9475814, 23 | CHEMBL3422017 | US10065961, Compou...)
Affinity DataKi: >1.00E+4nMAssay Description:NK2: Binding assays were performed in a 25 mM HEPES/1 mM CaCl2/5 mM MgCl2/0.5% BSA/10 μg/ml saponin, at pH 7.4. Binding assays consisted of 25 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081197(US9475814, 23 | CHEMBL3422017 | US10065961, Compou...)
Affinity DataKi: >1.00E+4nMAssay Description:NK1: The following radioligand: [3H] substance P (PerkinElmer Cat#NET111520) was used in this assay. Binding assays were performed in a 50 mM Tris/5 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US9475814, 11 | US10065961, Compound 11 | US106832...)
Affinity DataKi: >1.00E+4nMAssay Description:NK2: Binding assays were performed in a 25 mM HEPES/1 mM CaCl2/5 mM MgCl2/0.5% BSA/10 μg/ml saponin, at pH 7.4. Binding assays consisted of 25 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US9475814, 11 | US10065961, Compound 11 | US106832...)
Affinity DataKi: >1.00E+4nMAssay Description:NK1: The following radioligand: [3H] substance P (PerkinElmer Cat#NET111520) was used in this assay. Binding assays were performed in a 50 mM Tris/5 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

LigandPNGBDBM251922(US9475814, 22 | US10065961, Compound 22 | US106832...)
Affinity DataIC50: 1.20E+4nMAssay Description:hERG: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generat...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081195(US9475814, 1 | CHEMBL3422010 | US10065961, Compoun...)
Affinity DataKi:  1.27E+4nMAssay Description:NK1: The following radioligand: [3H] substance P (PerkinElmer Cat#NET111520) was used in this assay. Binding assays were performed in a 50 mM Tris/5 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50081195(US9475814, 1 | CHEMBL3422010 | US10065961, Compoun...)
Affinity DataKi:  1.40E+4nMAssay Description:NK2: Binding assays were performed in a 25 mM HEPES/1 mM CaCl2/5 mM MgCl2/0.5% BSA/10 μg/ml saponin, at pH 7.4. Binding assays consisted of 25 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2021
Entry Details
US Patent

Displayed 1 to 50 (of 59 total ) | Next | Last >>
Jump to: